Insider Selling: Omnicell (NASDAQ:OMCL) EVP Sells $133,549.80 in Stock

Posted by Brenda Bartman on May 22nd, 2026

Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the sale, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Price Performance

OMCL stock opened at $43.76 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 52-week low of $26.84 and a 52-week high of $55.00. The stock’s 50 day moving average is $37.90 and its two-hundred day moving average is $40.75. The company has a market capitalization of $1.99 billion, a PE ratio of 99.46, a P/E/G ratio of 1.16 and a beta of 0.96.

Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. During the same period in the previous year, the business earned $0.26 EPS. Omnicell’s revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Analysts predict that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently made changes to their positions in OMCL. AQR Capital Management LLC increased its holdings in shares of Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after acquiring an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after acquiring an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after acquiring an additional 4,866 shares during the last quarter. Jane Street Group LLC boosted its position in Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after purchasing an additional 109,382 shares during the period. Finally, Creative Planning boosted its position in Omnicell by 16.7% during the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after purchasing an additional 1,347 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Benchmark restated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Craig Hallum restated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $59.86.

View Our Latest Stock Report on OMCL

About Omnicell

(Get Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.